TKT and brain neoplasm: In contrast, clinical trials employing the HSV-TK/ GCV system and a retroviral vector have demonstrated only a limited effect in glioblastoma patients [4-8], implying that transfer and distribution of the transgene in human brain tumors were very low in vivo and differed obviously from the findings in animal experiments.